Search clinical trials for: Sodium-glucose cotransporter 2 inhibitor

Total 9220 results

National Institute of Allergy and Infectious Diseases...

Recruiting

Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency

Crohn's Disease | Glycogen Metabolism | Inflammatory Bowel Disease (IBD)

United States
Sun Jia

Completed

Effect of Dapagliflozin on Body Weight in Overweight Women Consuming Different Proportions of Carbohydrate Diet.

Overweight | Carbohydrate | Sodium-glucose Transporter 2 Inhibitors

China
Fundacion para la Formacion e Investigacion Sanitarias...
Spanish Society of Cardiology

Completed

Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure . (MODA)

Heart Failure

Spain
Medical University Innsbruck
Medical University of Graz; University of Bern

Completed

Dapagliflozin in Type 1 Diabetes (DapaT1DM)

Glycemic Control | Fasting Glucose | Glucose Excursion

Austria
Boehringer Ingelheim

Completed

A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017

Type 2 Diabetes Mellitus

Sweden
Huashan Hospital

Unknown

A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy

Cardiomyopathies | Acromegaly

China
AstraZeneca
Bristol-Myers Squibb

Completed

PK Study of Dapagliflozin in Pediatric Subjects With T2DM

Type 2 Diabetes Mellitus

United States, Mexico
AstraZeneca
Bristol-Myers Squibb

Completed

Renal Impairment in Type 2 Diabetic Subjects

Diabetes Mellitus, Type 2

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus

Type2 Diabetes | High Blood Sugar

Japan
AstraZeneca
Bristol-Myers Squibb

Completed

Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

Japan
The University of The West Indies

Completed

The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study. (EFFECT)

Platelet Dysfunction Due to Drugs

Trinidad and Tobago
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Effects of the Sodium-glucose Cotransporter 2 Inhibitors+Sacubitril/Valsartan Therapy in Patients With HFrEF.

Heart Failure | Ventricular Dysfunction | Ventricular Remodeling

Italy
Mohamed Nabil Elkholy

Recruiting

Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients

STEMI

Egypt
Chinese University of Hong Kong

Recruiting

Dapa Acute Heart Failure Study

Heart Failure

Hong Kong
China National Center for Cardiovascular Diseases

Recruiting

Dapagliflozin Therapy In Cardiac Surgery

Diabetes Mellitus, Type 2 | Cardiac Surgery

China
Children's Hospital of Fudan University

Completed

Efficacy and Safety of Dapagliflozin in Children With Proteinuria

Proteinuria

China
The University of Hong Kong

Active, not recruiting

The Effects of SGLTi on Diabetic Cardiomyopathy (SGLTi)

Type2 Diabetes | Heart Failure With Reduced Ejection Fraction

Hong Kong
University of Ioannina

Completed

Evaluation of the Tubular Effects of Dapagliflozin Using 1HNMR Spectroscopy

Diabetes

Greece
AstraZeneca
Bristol-Myers Squibb

Completed

Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes Mellitus

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers

Healthy

Germany
Seoul National University Hospital
AstraZeneca

Completed

Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell

Diabetes Mellitus, Type 2

Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...

Completed

The Effect of Food on the Administration of Canagliflozin in Healthy Adult Volunteers

Healthy
Pharmaceuticals and Medical Devices Agency, Japan

Unknown

Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Unity Health Toronto
Boehringer Ingelheim; Canadian Medical and Surgical Knowledge Translation Research... and other collaborators

Completed

Empagliflozin and Cardiac Remodelling in People Without Diabetes (EMPA-HEART 2)

Cardiovascular Diseases | Left Ventricular Hypertrophy

Canada, Taiwan
RWTH Aachen University
Boehringer Ingelheim

Completed

Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes (EMPA)

Diabetes Mellitus Type 2 (T2DM)

Germany
The People's Hospital of Gaozhou

Recruiting

The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients

The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients

China
Instituto Nacional de Ciencias Medicas y Nutricion...
Olynka Vega Vega; Noemi del Toro Cisneros; Miguel Ángel Martínez Rojas

Recruiting

Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study (DAKI-CKD)

Biomarkers | CKD | AKI - Acute Kidney Injury | Transition to CKD

Mexico
AstraZeneca

Terminated

The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function. (DAPASALT)

Diabetes Mellitus, Type 2 | Kidney Function Tests

Netherlands, Sweden
AstraZeneca

Completed

Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles. (DAPAMAAST)

Diabetes Mellitus, Type 2 | Skeletal Muscle Insulin Sensitivity

Netherlands
AstraZeneca
Bristol-Myers Squibb

Completed

A Study to to Assess the Effect of Dapagliflozin When Administered Once a Day Versus Twice a Day on Blood Glucose

Healthy Volunteers

Germany
Stanford University
Merck Sharp & Dohme LLC

Active, not recruiting

Ertugliflozin: Cardioprotective Effects on Epicardial Fat

Cardiovascular Diseases | Atherosclerosis | Insulin Resistance | Type 2 Diabetes

United States
McGill University Health Centre/Research Institute...
Diabetes Canada

Recruiting

Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes

Type 1 Diabetes

Canada
Xinhua Hospital, Shanghai Jiao Tong University...

Recruiting

Efficacy and Safety of Empagliflozin in GSD-Ib Patients

Glycogen Storage Disease Type IB

China
University Hospital Goettingen
German Research Foundation

Recruiting

Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients (DOUBLE_PROTECT)

Chronic Kidney Failure in Children and Young Adults

Germany
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Effect of Dapagliflozin on VT in Patients With Heart Failure.

Heart Failure
Assistance Publique - Hôpitaux de Paris

Recruiting

Cardiometabolic Effects of Dapagliflozin in Heart Failure With Reduced or Mildly Reduced Ejection Fraction (ICARD)

Heart Failure | Reduced Ejection Fraction

France
Wonju Severance Christian Hospital

Recruiting

Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes

Type2 Diabetes | Remodeling, Ventricular

Korea, Republic of
Hong Kong Children's Hospital

Recruiting

Prospective Cohort Study of Children With GSD1b Receiving Empagliflozin

Glycogen Storage Disease Type IB

Hong Kong
University of Sao Paulo General Hospital
Federal University of São Paulo

Recruiting

EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.

Diabetes Mellitus, Type 2 | Diabetes Complications | Kidney Transplantation

Brazil
The TIMI Study Group
AstraZeneca; Worldwide Clinical Trials

Recruiting

Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)

Heart Failure | Acute Heart Failure

United States
AstraZeneca
Fullcro s.r.l.

Completed

Observation of Italian Patients With Heart Failure Being Treated With Dapagliflozin in Clinical Practice (EVOLUTION-HF)

Heart Failure, Reduced Ejection Fraction

Italy
Boehringer Ingelheim

Completed

A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years

Diabetes Mellitus, Type 2

Japan
Boehringer Ingelheim

Completed

This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim

Completed

A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin

Diabetes Mellitus, Type 2

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

Myocardial Infarction

United States, Spain, Australia, Denmark, Netherlands, Canada, China, Germany, Korea, Republic of, Israel, Hungary, Japan, Argentina, France, Romania, Russian Federation, Serbia, Ukraine, Poland, India, Brazil, Bulgaria
AstraZeneca

Completed

Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease (MIRACLE)

Heart Failure | Chronic Kidney Disease

United States, Germany, Italy, Spain, Belgium, Denmark, Thailand, Poland, Canada, Korea, Republic of, Slovakia, Taiwan, Turkey, Ukraine, Japan, Czechia, Hungary, Bulgaria, Russian Federation, Sweden, Lithuania, India
Ohio State University
Diacomp

Withdrawn

Empagliflozin in Adolescent Diabetes

type1diabetes

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Tan Tock Seng Hospital

Withdrawn

Dapagliflozin Effect on Cardiovascular Outcomes in Haemodialysis for End Stage Renal Disease (DECODED)

Cardiovascular Diseases | End Stage Renal Disease
Icahn School of Medicine at Mount Sinai
Eli Lilly and Company; Boehringer Ingelheim

Completed

Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4). (EMPA-TROPISM)

Cardiovascular Diseases

United States

Search clinical trials for: Sodium-glucose cotransporter 2 inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations